Changes in chemokines and their receptors in blood during treatment with the TNF inhibitor infliximab in patients with rheumatoid arthritis

References

• St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, . Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432–43.
   PubMed Web of Science ®Google Scholar
• Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford) 2010;49:2313–21.
   PubMed Web of Science ®Google Scholar
• Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2: 244–7.
   PubMed Web of Science ®Google Scholar
• Scali JJ, Visentini S, Salomon J, Sevilla D, Ju YC, Morales E, . Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants. Ann N Y Acad Sci 2007;1110:389–401.
   PubMedGoogle Scholar
• Lindberg J, af Klint E, Catrina AI, Nilsson P, Klareskog L, Ulfgren AK, . Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 2006;8:R179.
   PubMed Web of Science ®Google Scholar
• Shen C, Maerten P, Geboes K, Van Assche G, Rutgeerts P, Ceuppens JL. Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin Immunol 2005;115:250–9.
   PubMed Web of Science ®Google Scholar
• Ringheanu M, Daum F, Markowitz J, Levine J, Katz S, Lin X, . Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn’s disease. Inflamm Bowel Dis 2004;10:801–10.
   PubMed Web of Science ®Google Scholar
• Wijbrandts CA, Remans PH, Klarenbeek PL, Wouters D, van den Bergh Weerman MA, Smeets TJ, . Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients. Arthritis Rheum 2008;58:3330–9.
   PubMedGoogle Scholar
• Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217–42.
   PubMed Web of Science ®Google Scholar
• Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007;25:787–820.
   PubMed Web of Science ®Google Scholar
• Hegen M, Camerini D, Fleischer B. Function of dipeptidyl peptidase IV (CD26, Tp103) in transfected human T cells. Cell Immunol 1993;146:249–60.
   PubMedGoogle Scholar
• Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53–73.
   PubMed Web of Science ®Google Scholar
• Preller V, Gerber A, Wrenger S, Togni M, Marguet D, Tadje J, . TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26. J Immunol 2007;178:4632–40.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van ‘t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44–8.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, . American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
   PubMed Web of Science ®Google Scholar
• Hanaoka R, Kasama T, Muramatsu M, Yajima N, Shiozawa F, Miwa Y, . A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 2003;5:R74–81.
   Google Scholar
• Gasperini S, Marchi M, Calzetti F, Laudanna C, Vicentini L, Olsen H, . Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils. J Immunol 1999;162:4928–37.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Takahashi M. IFN-gamma-mediated survival enables human neutrophils to produce MCP-1/CCL2 in response to activation by TLR ligands. J Immunol 2007;179:1942–9.
   PubMedGoogle Scholar
• Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003;24:25–9.
   PubMed Web of Science ®Google Scholar
• Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 2006;24:529–33.
   PubMed Web of Science ®Google Scholar
• Torikai E, Kageyama Y, Suzuki M, Ichikawa T, Nagano A. The effect of infliximab on chemokines in patients with rheumatoid arthritis. Clin Rheumatol 2007;26:1088–93.
   PubMedGoogle Scholar
• Kobayashi H, Hosono O, Mimori T, Kawasaki H, Dang NH, Tanaka H, . Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus. J Rheumatol 2002;29:1858–66.
   PubMed Web of Science ®Google Scholar
• Busso N, Wagtmann N, Herling C, Chobaz-Peclat V, Bischof-Delaloye A, So A, . Circulating CD26 is negatively associated with inflammation in human and experimental arthritis. Am J Pathol 2005;166:433–42.
   PubMedGoogle Scholar
• Ellingsen T, Hornung N, Moller BK, Hjelm-Poulsen J, Stengaard-Pedersen K. In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. Scand J Immunol 2007;66:451–7.
   PubMedGoogle Scholar
• Seitzer U, Scheel-Toellner D, Mattern T, Haas H, Flad HD, Gerdes J. Staining pattern of seven monoclonal anti-CD26 antibodies in leprosy: implications for the use of CD26 as a surrogate marker of a human Th1-like reaction. Virchows Arch 1998;432:343–7.
   PubMedGoogle Scholar
• Aeberli D, Seitz M, Juni P, Villiger PM. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. Rheumatology (Oxford) 2005;44: 172–5.
   PubMed Web of Science ®Google Scholar
• Mohan K, Issekutz TB. Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J Immunol 2007;179:8463–9.
   PubMed Web of Science ®Google Scholar
• Ruth JH, Rottman JB, Katschke KJ Jr, Qin S, Wu L, LaRosa G, . Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001;4: 2750–60.
   Google Scholar
• Nissinen R, Leirisalo-Repo M, Peltomaa R, Palosuo T, Vaarala O. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 2004;63:681–7.
   PubMed Web of Science ®Google Scholar
• Xia L, Lu J, Xiao W. Blockage of TNF-alpha by infliximab reduces CCL2 and CCR2 levels in patients with rheumatoid arthritis. J Investig Med 2011;59:961–3.
   PubMedGoogle Scholar
• Kuziel WA, Morgan SJ, Dawson TC, Griffin S, Smithies O, Ley K, . Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc Natl Acad Sci USA 1997;94:12053–8.
   PubMed Web of Science ®Google Scholar
• Weber C, Draude G, Weber KS, Wubert J, Lorenz RL, Weber PC. Downregulation by tumor necrosis factor-alpha of monocyte CCR2 expression and monocyte chemotactic protein-1-induced transendothelial migration is antagonized by oxidized low-density lipoprotein: a potential mechanism of monocyte retention in atherosclerotic lesions. Atherosclerosis 1999;145:115–23.
   PubMed Web of Science ®Google Scholar
• Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, . A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2387–92.
   PubMed Web of Science ®Google Scholar
• Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, . Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008;58:1931–9.
   PubMed Web of Science ®Google Scholar
• Ellingsen T, Hornung N, Moller BK, Poulsen JH, Stengaard-Pedersen K. Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders. Ann Rheum Dis 2007;66:151–7.
   PubMed Web of Science ®Google Scholar
• Bruhl H, Cihak J, Schneider MA, Plachy J, Rupp T, Wenzel I, . Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J Immunol 2004;172:890–8.
   PubMed Web of Science ®Google Scholar